BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Share this content:
BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Sponsors and Collaborators
Bristol-Myers Squibb
Ono Pharmaceutical Company, Ltd.

Principal Investigator
Bristol-Myers Squibb, Bristol-Myers Squibb

ClinicalTrials.gov Identifier
NCT01472081

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters